No analytical assay is currently available for the simultaneous determination of CBD major metabolites in serum or urine samples of individuals treated with medical cannabis or CBD-based pharmaceuticals. We developed and validated a method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC–MS/MS) for quantifying cannabidiol (CBD) and its metabolites, cannabidiol-7-oic acid (7-COOH-CBD), 7- hydroxycannabidiol (7-OH-CBD), 6-alpha-hydroxycannabidiol (6-α–OH–CBD) and 6-beta-hydroxycannabidiol (6-β–OH–CBD) in serum and urine samples of an individual treated with medical cannabis. The ionization was performed by electrospray in negative mode to reach the sensitivity required to detect trace amounts, with limits of quantification

ranging from 0.05 to 0.1 ng/mL. The method is accurate (average inter/intra-day error, <15%), precise (inter/intra-day imprecision, <15%) and fast (8 min run time) and it is an essential tool to investigate CBD pharmacokinetics and pharmacodynamics in individuals treated with medical cannabis or with CBD-based medical preparations.

当前没有分析测定可用于同时测定用医用大麻或基于CBD的药物治疗的个体的血清或尿液样品中的CBD主要代谢物。我们开发并验证了一种使用超高效液相色谱与串联质谱（UHPLC–MS / MS）结合在一起的方法来定量测定大麻二酚（CBD）及其代谢产物大麻二酚-7-油酸（7-COOH-CBD）的方法，接受过下列药物治疗的个体的血清和尿液样品中的7-羟基大麻二酚（7-OH-CBD），6-α-羟基大麻二酚（6-α-OH-CBD）和6-β-羟基大麻二酚（6-β-OH-CBD）医用大麻。通过电喷雾在负离子模式下进行电离，以达到检测痕量所需的灵敏度，并且存在定量限制

范围从0.05到0.1 ng / mL。该方法是准确的（日间/日间平均误差，<15％），精确的（日间/日内不精确度，<15％）和快速（8分钟的运行时间），是研究CBD药代动力学和代谢动力学的重要工具。用医用大麻或基于CBD的医疗制剂治疗的个体的药效学。